EGFR and non-small cell lung carcinoma: In 2013, the Food and Drug Administration (FDA) approved erlotinib (Tarceva®) as a first-line treatment for metastatic NSCLC patients with EGFR mutations.7 The NCCN also recommended erlotinib as a first-line therapy in patients with sensitizing EGFR mutations.